• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非诺贝特-辛伐他汀固体分散体在开发用于治疗脂质紊乱的固定剂量制剂中的筛选。

Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders.

作者信息

Górniak Agata, Czapor-Irzabek Hanna, Złocińska Adrianna, Gawin-Mikołajewicz Agnieszka, Karolewicz Bożena

机构信息

Laboratory of Elemental Analysis and Structural Research, Wroclaw Medical University, Borowska 211A, 50-556 Wroclaw, Poland.

Department of Drug Form Technology, Wroclaw Medical University, Borowska 211A, 50-556 Wroclaw, Poland.

出版信息

Pharmaceutics. 2023 Feb 10;15(2):603. doi: 10.3390/pharmaceutics15020603.

DOI:10.3390/pharmaceutics15020603
PMID:36839925
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9962408/
Abstract

The combination of statins and fibrates in the treatment of lipid abnormalities effectively regulates individual lipid fraction levels. In this study, the screening and assessment of the physicochemical properties of simvastatin-fenofibrate solid dispersions were performed. Fenofibrate and simvastatin were processed using the kneading method in different weight ratios, and the resulting solid dispersions were assessed using differential scanning calorimetry (DSC), X-ray powder diffractometry (XRPD), Fourier-transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), contact angle, as well as dissolution tests. The obtained results confirmed the formation of a simple eutectic phase diagram, with a eutectic point containing 79 wt% fenofibrate and 21 wt% simvastatin, lack of chemical interactions between the ingredients, and simvastatin impact on improving fenofibrate dissolution profile, due to the formation of crystalline solid dispersions by the kneading method.

摘要

他汀类药物与贝特类药物联合用于治疗脂质异常可有效调节各个脂质组分的水平。在本研究中,对辛伐他汀 - 非诺贝特固体分散体的物理化学性质进行了筛选和评估。采用捏合法以不同重量比处理非诺贝特和辛伐他汀,并使用差示扫描量热法(DSC)、X射线粉末衍射法(XRPD)、傅里叶变换红外光谱法(FTIR)、扫描电子显微镜(SEM)、接触角以及溶出度试验对所得固体分散体进行评估。获得的结果证实形成了简单的低共熔相图,其低共熔点含有79 wt%的非诺贝特和21 wt%的辛伐他汀,成分之间不存在化学相互作用,并且由于通过捏合法形成了结晶固体分散体,辛伐他汀对改善非诺贝特的溶出曲线有影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d772/9962408/6f9bb5455a70/pharmaceutics-15-00603-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d772/9962408/29a5a23d5fba/pharmaceutics-15-00603-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d772/9962408/76a73ede04ca/pharmaceutics-15-00603-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d772/9962408/bc388efd39ad/pharmaceutics-15-00603-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d772/9962408/efd12c80e511/pharmaceutics-15-00603-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d772/9962408/46d31c0a4ba6/pharmaceutics-15-00603-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d772/9962408/2db4d1fb5b31/pharmaceutics-15-00603-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d772/9962408/1637ead6ebfa/pharmaceutics-15-00603-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d772/9962408/093ee229980c/pharmaceutics-15-00603-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d772/9962408/a288e3cb2515/pharmaceutics-15-00603-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d772/9962408/8c995c045739/pharmaceutics-15-00603-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d772/9962408/aff0da3a1921/pharmaceutics-15-00603-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d772/9962408/6f9bb5455a70/pharmaceutics-15-00603-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d772/9962408/29a5a23d5fba/pharmaceutics-15-00603-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d772/9962408/76a73ede04ca/pharmaceutics-15-00603-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d772/9962408/bc388efd39ad/pharmaceutics-15-00603-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d772/9962408/efd12c80e511/pharmaceutics-15-00603-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d772/9962408/46d31c0a4ba6/pharmaceutics-15-00603-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d772/9962408/2db4d1fb5b31/pharmaceutics-15-00603-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d772/9962408/1637ead6ebfa/pharmaceutics-15-00603-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d772/9962408/093ee229980c/pharmaceutics-15-00603-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d772/9962408/a288e3cb2515/pharmaceutics-15-00603-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d772/9962408/8c995c045739/pharmaceutics-15-00603-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d772/9962408/aff0da3a1921/pharmaceutics-15-00603-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d772/9962408/6f9bb5455a70/pharmaceutics-15-00603-g012.jpg

相似文献

1
Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders.非诺贝特-辛伐他汀固体分散体在开发用于治疗脂质紊乱的固定剂量制剂中的筛选。
Pharmaceutics. 2023 Feb 10;15(2):603. doi: 10.3390/pharmaceutics15020603.
2
Preformulation Studies of Ezetimibe-Simvastatin Solid Dispersions in the Development of Fixed-Dose Combinations.依折麦布-辛伐他汀固体分散体在固定剂量复方制剂研发中的处方前研究
Pharmaceutics. 2022 Apr 22;14(5):912. doi: 10.3390/pharmaceutics14050912.
3
Physicochemical and dissolution studies of simvastatin solid dispersions with Pluronic F127.辛伐他汀与普朗尼克F127固体分散体的物理化学及溶出度研究
Pharmazie. 2014 Aug;69(8):589-94.
4
Formulation and delivery of improved amorphous fenofibrate solid dispersions prepared by thin film freezing.薄膜冷冻法制备和传递改良非诺贝特无定形固体分散体。
Eur J Pharm Biopharm. 2012 Nov;82(3):534-44. doi: 10.1016/j.ejpb.2012.06.016. Epub 2012 Sep 5.
5
Physicochemical characterization and in vitro dissolution studies of solid dispersions of ketoprofen with PVP K30 and d-mannitol.酮洛芬与 PVP K30 和 D-甘露醇固体分散体的理化性质表征及体外溶出度研究。
Saudi Pharm J. 2013 Jan;21(1):77-84. doi: 10.1016/j.jsps.2011.12.007. Epub 2011 Dec 24.
6
Factors affecting the formation of eutectic solid dispersions and their dissolution behavior.影响低共熔固体分散体形成及其溶解行为的因素。
J Pharm Sci. 2007 Feb;96(2):294-304. doi: 10.1002/jps.20754.
7
Rapid disintegrating tablets of simvastatin dispersions in polyoxyethylene-polypropylene block copolymer for maximized disintegration and dissolution.辛伐他汀在聚氧乙烯-聚丙稀嵌段共聚物中的速崩片,用于实现最大化崩解和溶解。
Drug Des Devel Ther. 2016 Oct 3;10:3211-3223. doi: 10.2147/DDDT.S114724. eCollection 2016.
8
Enhancement of dissolution profile by solid dispersion (kneading) technique.采用固体分散体(捏合)技术提高溶出度曲线
AAPS PharmSciTech. 2006 Aug 18;7(3):68. doi: 10.1208/pt070368.
9
Preparation, characterization and in vitro evaluation of tablets containing microwave-assisted solid dispersions of apremilast.含有阿普斯特微波辅助固体分散体的片剂的制备、表征及体外评价
Polim Med. 2018 Jan-Jun;48(1):17-24. doi: 10.17219/pim/99801.
10
Properties of rapidly dissolving eutectic mixtures of poly(ethylene glycol) and fenofibrate: the eutectic microstructure.聚乙二醇与非诺贝特快速溶解低共熔混合物的性质:低共熔微观结构
J Pharm Sci. 2003 Mar;92(3):505-15. doi: 10.1002/jps.10324.

本文引用的文献

1
Single-pill fixed-dose drug combinations to reduce blood pressure: the right pill for the right patient.单片固定剂量复方制剂用于降低血压:为合适的患者选择合适的药物。
Ther Adv Chronic Dis. 2022 Jun 24;13:20406223221102754. doi: 10.1177/20406223221102754. eCollection 2022.
2
The Development of Innovative Dosage Forms of the Fixed-Dose Combination of Active Pharmaceutical Ingredients.活性药物成分固定剂量组合的创新剂型研发
Pharmaceutics. 2022 Apr 11;14(4):834. doi: 10.3390/pharmaceutics14040834.
3
Ternary Eutectic Ezetimibe-Simvastatin-Fenofibrate System and the Physical Stability of Its Amorphous Form.
三元共晶ezetimibe-辛伐他汀-非诺贝特系统及其无定形形式的物理稳定性。
Mol Pharm. 2021 Sep 6;18(9):3588-3600. doi: 10.1021/acs.molpharmaceut.1c00485. Epub 2021 Aug 22.
4
Eutectic mixtures as an approach to enhance solubility, dissolution rate and oral bioavailability of poorly water-soluble drugs.共晶混合物作为一种提高低水溶性药物溶解度、溶出速率和口服生物利用度的方法。
Int J Pharm. 2020 Oct 15;588:119741. doi: 10.1016/j.ijpharm.2020.119741. Epub 2020 Aug 9.
5
Development of a Discriminative and Biorelevant Dissolution Test Method for Atorvastatin/Fenofibrate Combination with Appliance of Derivative Spectrophotometry.采用导数分光光度法建立阿托伐他汀/非诺贝特组合制剂的鉴别性和生物相关性溶出度测试方法。
Turk J Pharm Sci. 2019 Mar;16(1):62-68. doi: 10.4274/tjps.77698. Epub 2018 Dec 31.
6
Fixed dose drug combinations - are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries.固定剂量药物组合 - 它们在药物经济学上是否合理?特别是对中低收入国家的发现和影响。
Expert Rev Pharmacoecon Outcomes Res. 2020 Feb;20(1):1-26. doi: 10.1080/14737167.2020.1734456. Epub 2020 Apr 1.
7
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.2019年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南:通过血脂修饰降低心血管风险
Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455.
8
Metabolic syndrome and subsequent risk of type 2 diabetes and cardiovascular disease in elderly women: Challenging the current definition.老年女性的代谢综合征及后续患2型糖尿病和心血管疾病的风险:对当前定义提出挑战
Medicine (Baltimore). 2016 Sep;95(36):e4806. doi: 10.1097/MD.0000000000004806.
9
A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality.低密度脂蛋白胆固醇、治疗策略及其对心血管疾病发病率和死亡率影响的综述。
J Clin Lipidol. 2016 May-Jun;10(3):472-89. doi: 10.1016/j.jacl.2015.11.010. Epub 2015 Nov 25.
10
The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia.依折麦布与辛伐他汀联合用药治疗高胆固醇血症的安全性。
Expert Opin Drug Saf. 2016;15(4):559-69. doi: 10.1517/14740338.2016.1157164. Epub 2016 Mar 16.